Cosentyx is the brand name for secukinumab, a human monoclonal antibody that targets IL-17A and is used in inflammatory immune-mediated diseases. It is approved for psoriasis, psoriatic arthritis, ankylosing spondylitis, and hidradenitis suppurativa, with additional approved indications in some regions. It is prescription-only.
Novartis is emphasizing innovative medicines across oncology, immunology, neuroscience and gene therapy. The company targets mid-single-digit sales growth through 2027 and core operating income margins above 35%.
Orphan drug sales are projected to reach $400 billion by 2032, accounting for over 21% of prescription drug sales. Recent policy changes expanded IRA exemptions for multi-indication orphan drugs and reauthorized pediatric review vouchers. Johnson & Johnson's Darzalex leads orphan drug sales with $31 billion projected revenue.
The FDA announced major policy changes including requiring only one study for drug approvals instead of two, and offering performance bonuses to reviewers who complete work ahead of schedule while maintaining thoroughness.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT05522517 |
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 4 |
COMPLETED | PHASE1 |
| NCT04589026 |
A Study Validating the Use of Candin as a Challenge Agent in Healthy Participants - Intervention Specific Appendix 1 |
COMPLETED | PHASE1 |
| NCT03651518 |
Personalized Therapies in Inflammatory Complex Disease |
COMPLETED | PHASE2 |
| NCT03342573 |
Cosentyx (Secukinumab) for the Treatment of Adult Onset Pityriasis Rubra Pilaris |
COMPLETED | PHASE1 |
